Deucravacitinib-treated patients achieved superior clinical responses compared to placebo at week 16 in both trials.
Roland Chen, MD
Advertisement
Roland Chen, MD, is the senior vice president of drug development for immunology and cardiovascular at Bristol Myers Squibb.
Articles by Roland Chen, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Dermatology Times
1
Dermalogica Enters Medical Aesthetics with FDA-Cleared Microneedling PRO Pen
2
Social Media Mythbusters: Hypochlorous Acid Sprays
3
Quoin Submits First-Ever IND Application for Peeling Skin Syndrome Therapy
4
Topical GX-03 Hits 92.6% EASI-50 at Week 4 in Phase 2 AD Interim
5